Drawing for LYMPHOTRACK FLEX

USPTO serial 99124750

LYMPHOTRACK FLEX

Reviewed by CopyMark Law Group

Reg. 8395482Status 700Registered
Filing date
Status date
Registration date
Aug 11, 2026
Examiner
CONNERS,LAUREN G
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LYMPHOTRACK FLEX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sarah W. Matthews

Sarah W. Matthews Dentons Durham Jones Pinegar1557 W Innovation Way, Suite 400Lehi, UT 84043United States

Goods and services

ClassDescriptionStatusFirst use
001Reagents for scientific and research use, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of chemical and biological reagents for non-medical purposes; diagnostic reagents for scientific and research use; diagnostic assays for research, clinical or medical laboratory useACTIVENov 24, 2025
005Assays for the treatment or diagnosis of disease; medical diagnostic reagents, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic kits comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic reagent kits comprised of chemical and biological reagents for the treatment, monitoring and diagnosis of disease; medical diagnostic reagent kits comprised of medical reagents for clinical or medical use; medical diagnostic assays for the treatment and diagnosis of disease; medical diagnostic assays for research, clinical and medical useACTIVENov 24, 2025

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 11, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 11, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 21, 2026SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jul 21, 2026CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 18, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 18, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 8, 2026IUAFUSE AMENDMENT FILED—
May 8, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Dec 9, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 14, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 14, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 8, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 16, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 3, 2025DOCKASSIGNED TO EXAMINER—
Jul 11, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 28, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 28, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 28, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 7, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 7, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance